Healthcare and life sciences, forward
Sutter Health's planned $1 billion investment in Northern California's East Bay region will no longer include a new flagship medical center, at least for now. Outpatient investments in the community will still be going forward.
Companies have spent the past several weeks trying to reassure investors that Muse and other AI agents pose more of an opportunity than a threat.
A biotech startup let an agent choose a gene therapy and successfully inject the treatment, offering a startling glimpse of the future of research labs.
The health system's push into high-acuity procedures like joint replacements and spinal fusions helped offset declining surgical volumes and payer-mix pressures tied to the ACA exchanges.
An increasing shift toward outpatient surgeries and slower-than-expected ramps to profitability at some of its hospitals dinged Universal Health Services’ earnings in the third quarter.
This week on Uncanny Valley, we also discuss Anthropic’s IPO filing and the volunteers gearing up to counter ICE at the midterms.
Research released by the clinical AI company shows that its dose verification tool outperformed general-use AI models, which it says are rife with errors. It’s Doximity’s latest play to stand out as major AI companies forge into healthcare.
